{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:43:57Z","timestamp":1780321437054,"version":"3.54.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1097\/fpc.0000000000000289","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T17:04:46Z","timestamp":1497719086000},"page":"285-293","source":"Crossref","is-referenced-by-count":14,"title":["Genetic coding variants in the niacin receptor, hydroxyl\u2013carboxylic acid receptor 2, and response to niacin therapy"],"prefix":"10.1097","volume":"27","author":[{"given":"Sony","family":"Tuteja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"DerOhannessian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M.","family":"Marcovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Elam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Lader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210213","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"key":"R2-2-20210213","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"R3-2-20210213","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J Intern Med"},{"key":"R4-2-20210213","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"R5-2-20210213","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"R6-2-20210213","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"R7-2-20210213","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R8-2-20210213","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R9-2-20210213","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"R10-2-20210213","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R11-2-20210213","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"R12-2-20210213","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"R13-2-20210213","doi-asserted-by":"crossref","first-page":"148ra115","DOI":"10.1126\/scitranslmed.3003877","article-title":"Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression","volume":"4","author":"Lauring","year":"2012","journal-title":"Sci Transl Med"},{"key":"R14-2-20210213","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"R15-2-20210213","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.17.10.2020","article-title":"Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport","volume":"17","author":"Jin","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R16-2-20210213","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/ATVBAHA.108.171363","article-title":"Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice","volume":"28","author":"Van der Hoorn","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R17-2-20210213","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI41651","article-title":"Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells","volume":"121","author":"Lukasova","year":"2011","journal-title":"J Clin Invest"},{"key":"R18-2-20210213","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1172\/JCI42273","article-title":"Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice","volume":"120","author":"Hanson","year":"2010","journal-title":"J Clin Invest"},{"key":"R19-2-20210213","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1152\/ajpendo.91004.2008","article-title":"Niacin stimulates adiponectin secretion through the GPR109A receptor","volume":"296","author":"Plaisance","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R20-2-20210213","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/ATVBAHA.111.241836","article-title":"Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms","volume":"32","author":"Digby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R21-2-20210213","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/ATVBAHA.109.201129","article-title":"Evidence that niacin inhibits Acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids","volume":"30","author":"Wu","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R22-2-20210213","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erc.12.134","article-title":"Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies","volume":"11","author":"Aslibekyan","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R23-2-20210213","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R24-2-20210213","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/humu.20121","article-title":"Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors","volume":"25","author":"Zellner","year":"2005","journal-title":"Hum Mutat"},{"key":"R25-2-20210213","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R26-2-20210213","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/gepi.20217","article-title":"Genetic model testing and statistical power in population-based association studies of quantitative traits","volume":"31","author":"Lettre","year":"2007","journal-title":"Genet Epidemiol"},{"key":"R27-2-20210213","doi-asserted-by":"crossref","first-page":"e002642","DOI":"10.1161\/JAHA.112.002642","article-title":"Heuristic methods for finding pathogenic variants in gene coding sequences","volume":"1","author":"Ohanian","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"R28-2-20210213","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/mol.105.015750","article-title":"Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A\/PUMA-G)","volume":"68","author":"Tunaru","year":"2005","journal-title":"Mol Pharmacol"},{"key":"R29-2-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(24)01478-9","article-title":"Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling","volume":"53","author":"Ferguson","year":"2001","journal-title":"Pharmacol Rev"},{"key":"R30-2-20210213","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1124\/mol.112.081307","article-title":"Identification and characterization of distinct c-terminal domains of the human hydroxycarboxylic acid receptor-2 that are essential for receptor export, constitutive activity, desensitization, and internalization","volume":"82","author":"Li","year":"2012","journal-title":"Mol Pharmacol"},{"key":"R32-2-20210213","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacc.2012.04.038","article-title":"Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R33-2-20210213","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1172\/JCI114395","article-title":"Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV\/Kringle V encoding domains in the apo(a) gene","volume":"84","author":"Gavish","year":"1989","journal-title":"J Clin Invest"},{"key":"R34-2-20210213","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2013.06.008","article-title":"Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential","volume":"25","author":"Gaidarov","year":"2013","journal-title":"Cell Signal"},{"key":"R35-2-20210213","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bcp.2003.09.014","article-title":"Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin","volume":"67","author":"Rubic","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R36-2-20210213","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1096\/fj.05-4857fje","article-title":"Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin","volume":"20","author":"Sotiriou","year":"2006","journal-title":"FASEB J"},{"key":"R37-2-20210213","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J Lipid Res"},{"key":"R38-2-20210213","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1096\/fj.12-223933","article-title":"The role of HCA2 (GPR109A) in regulating macrophage function","volume":"27","author":"Zandi-Nejad","year":"2013","journal-title":"FASEB J"},{"key":"R39-2-20210213","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.metabol.2015.10.001","article-title":"Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2","volume":"65","author":"Graff","year":"2016","journal-title":"Metabolism"},{"key":"R40-2-20210213","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.tips.2006.05.008","article-title":"The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target","volume":"27","author":"Offermanns","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"R41-2-20210213","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/ncomms6068","article-title":"Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins","volume":"5","author":"Postmus","year":"2014","journal-title":"Nat Commun"},{"key":"R42-2-20210213","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"R43-2-20210213","doi-asserted-by":"crossref","first-page":"26649","DOI":"10.1074\/jbc.C500213200","article-title":"(D)-\u03b2-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G","volume":"280","author":"Taggart","year":"2005","journal-title":"J Biol Chem"},{"key":"R44-2-20210213","doi-asserted-by":"crossref","first-page":"21928","DOI":"10.1074\/jbc.M109.019455","article-title":"Deorphanization of GPR109B as a receptor for the \u03b2-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis","volume":"284","author":"Ahmed","year":"2009","journal-title":"J Biol Chem"},{"key":"R45-2-20210213","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"Marcovina","year":"1996","journal-title":"J Lipid Res"},{"key":"R46-2-20210213","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.","volume":"302","author":"Collaboration","year":"2009","journal-title":"JAMA"},{"key":"R47-2-20210213","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"R48-2-20210213","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"R49-2-20210213","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lp(a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:54:03Z","timestamp":1750359243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201708000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000289","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}